Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

NCT01298219 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

439

Enrollment

INDUSTRY

Sponsor class

Conditions

Opioid-induced Bowel Dysfunction

Interventions

DRUG: Lubiprostone
DRUG: Placebo

Sponsor

Sucampo Pharma Americas, LLC

Collaborators

[object Object]